{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:30:51Z","timestamp":1765294251065},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.beha.2006.11.005","type":"journal-article","created":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T21:29:55Z","timestamp":1172784595000},"page":"5-12","source":"Crossref","is-referenced-by-count":23,"title":["The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age"],"prefix":"10.1016","volume":"20","author":[{"given":"Kenneth","family":"Kaushansky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2006.11.005_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-2006-942754","article-title":"The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders","volume":"32","author":"Michiels","year":"2006","journal-title":"Seminars in Thrombosis and Hemostasis"},{"key":"10.1016\/j.beha.2006.11.005_bib3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beha.2005.07.013","article-title":"Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy","volume":"19","author":"Gotlib","year":"2006","journal-title":"Best Practice & Research. Clinical Haematology"},{"key":"10.1016\/j.beha.2006.11.005_bib4","first-page":"64","article-title":"Clinical, genetic, and therapeutic insights into systemic mast cell disease","volume":"11","author":"Terreri","year":"2004","journal-title":"Current Opinion in Hematology"},{"key":"10.1016\/j.beha.2006.11.005_bib5","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng0693-108","article-title":"Erythropoietin receptor mutations and Olympic glory","volume":"4","author":"Longmore","year":"1993","journal-title":"Nature Genetics"},{"key":"10.1016\/j.beha.2006.11.005_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.1162","article-title":"Genetic heterogeneity of primary familial and congenital polycythemia","volume":"68","author":"Kralovics","year":"2001","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.beha.2006.11.005_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng1019","article-title":"Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia","volume":"32","author":"Ang","year":"2002","journal-title":"Nature Genetics"},{"key":"10.1016\/j.beha.2006.11.005_bib9","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood.V95.11.3280","article-title":"Translational pathophysiology: a novel molecular mechanism of human disease","volume":"95","author":"Cazzola","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib10","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.beha.2006.11.005_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/stem.5530080716","article-title":"Erythropoietin receptor: cloning strategy and structural features","volume":"8","author":"D'Andrea","year":"1990","journal-title":"International Journal of Cell Cloning"},{"key":"10.1016\/j.beha.2006.11.005_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ng0693-124","article-title":"Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene","volume":"4","author":"Tsui","year":"1993","journal-title":"Nature Genetics"},{"key":"10.1016\/j.beha.2006.11.005_bib13","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood.V88.5.1656.1656","article-title":"Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation","volume":"88","author":"Cocault","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood.V88.4.1399.bloodjournal8841399","article-title":"Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer","volume":"88","author":"Onishi","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.V88.2.402.bloodjournal882402","article-title":"A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation","volume":"88","author":"Yan","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib16","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1101\/gad.12.11.1610","article-title":"Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span","volume":"12","author":"Helgason","year":"1998","journal-title":"Genes & Development"},{"key":"10.1016\/j.beha.2006.11.005_bib17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1203\/01.PDR.0000113462.98851.2E","article-title":"Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia","volume":"55","author":"Gitler","year":"2004","journal-title":"Pediatric Research"},{"key":"10.1016\/j.beha.2006.11.005_bib18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI20476","article-title":"Conditional expression of oncogenic K-ras from its endogenous\u00a0promoter induces a myeloproliferative disease","volume":"113","author":"Chan","year":"2004","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2006.11.005_bib19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4161\/cc.3.5.827","article-title":"Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia","volume":"3","author":"Chan","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.beha.2006.11.005_bib20","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Letter: Bone-marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2006.11.005_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1172\/JCI108706","article-title":"Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin","volume":"59","author":"Zanjani","year":"1977","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2006.11.005_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood.V80.4.891.891","article-title":"Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor","volume":"80","author":"Dai","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2141.1994.tb05065.x","article-title":"Polycythaemia vera. IV. Specific binding of stem cell factor to normal and polycythaemia vera highly purified erythroid progenitor cells","volume":"88","author":"Dai","year":"1994","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2006.11.005_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V83.1.99.99","article-title":"Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium","volume":"83","author":"Correa","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib25","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","article-title":"Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia","volume":"96","author":"Axelrad","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib26","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.86.5.1603","article-title":"Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction","volume":"86","author":"Wilks","year":"1989","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1016\/j.beha.2006.11.005_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0092-8674(92)90105-L","article-title":"A protein tyrosine kinase in the interferon alpha\/beta signaling pathway","volume":"70","author":"Velazquez","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.beha.2006.11.005_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/377591a0","article-title":"Cytokine receptor signalling","volume":"377","author":"Ihle","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.beha.2006.11.005_bib29","doi-asserted-by":"crossref","first-page":"30237","DOI":"10.1074\/jbc.272.48.30237","article-title":"Cytokine receptor-independent, constitutively active variants of STAT5","volume":"272","author":"Berchtold","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.beha.2006.11.005_bib30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0301-472X(01)00637-3","article-title":"STAT3 is constitutively active in some patients with Polycythemia rubra vera","volume":"29","author":"Roder","year":"2001","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.beha.2006.11.005_bib31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2006.11.005_bib32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2006.11.005_bib33","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.beha.2006.11.005_bib34","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2006.11.005_bib35","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib36","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10428190500301348","article-title":"JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?","volume":"47","author":"Nelson","year":"2006","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.beha.2006.11.005_bib38","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1091\/mbc.E02-06-0342","article-title":"Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain","volume":"14","author":"Saharinen","year":"2003","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.beha.2006.11.005_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Engineering"},{"key":"10.1016\/j.beha.2006.11.005_bib40","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the USA"},{"key":"10.1016\/j.beha.2006.11.005_bib41","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib42","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2005-04-1515","article-title":"The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients","volume":"106","author":"Goerttler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib44","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2006.11.005_bib45","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.4049\/jimmunol.176.11.6425","article-title":"Monocyte\/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin","volume":"176","author":"Wagner-Ballon","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.beha.2006.11.005_bib46","article-title":"Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF)","author":"Michiels","year":"2006","journal-title":"Pathologie-biologie"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T08:38:20Z","timestamp":1587371900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692606000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S1521692606000855"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2006.11.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}